Objective  To explore the effects of dapagliflozin on blood glucose and cognitive function in patients with type 2 diabetes mellitus (T2DM) and ischemic stroke (IS).

Methods  Patients with T2DM and IS admitted to the Department of Neurology, Beijing Tiantan Hospital, Capital Medical University from January 2022 to January 2023 were collected and randomly divided into dapagliflozin group (conventional treatment + dapagliflozin) and control group (conventional treatment+metformin) for 6 months of continuous treatment. Blood glucose control levels and fluctuations were compared before and after treatment. The Montreal Cognitive Assessment (MoCA) was used to evaluate cognitive function before and after treatment.

Results  A total of 100 patients were included in the study, 50 in the dapagliflozin group and 50 in the control group. After 6 months of treatment, blood glucose levels and fluctuations decreased in both groups (P<0.05), but were lower in the dapagliflozin group (P<0.05). Regarding cognitive function, MoCA scores increased in both groups, with the dapagliflozin group showing higher scores, especially in visuospatial executive function and delayed recall (P<0.05).

Conclusion  Dapagliflozin can effectively control blood glucose levels and fluctuations in T2DM patients with IS, and improve cognitive function, particularly in visuospatial executive function and delayed recall.

1.Tsivgoulis G, Katsanos AH, Sandset EC, et al. Thrombolysis for acute ischaemic stroke: current status and future perspectives[J]. Lancet Neurol, 2023, 22(5): 418-429. DOI: 10.1016/S1474-4422(22)00519-1.

2.Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative Meta-analysis of 102 prospective studies[J]. Lancet, 2010, 375(9733): 2215-2222. DOI: 10.1016/S0140-6736(10)60484-9.

3.van Asch CJ, Luitse MJ, Rinkel GJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and Meta-analysis[J]. Lancet Neurol, 2010, 9(2): 167-176. DOI: 10.1016/S1474-4422(09)70340-0.

4.姜嫄, 杨文娟. 达格列净对老年2型糖尿病肾病患者肾功能及血管内皮因子的影响观察[J]. 中国药师, 2022, 25(6): 1032-1036. [Jiang Y, Yang WJ. Observation of the effect of dapagliflozin on renal function and endothelial factors in elderly patients with type 2 diabetic nephropathy[J]. Chinese Pharmacist, 2022, 25(6): 1032-1036.] DOI: 10.19962/j.cnki.issn1008-049X.2022.06.017.

5.Frantellizzi V, Conte M, De Vincentis G. Hybrid Imaging of vascular cognitive impairment[J]. Semin Nucl Med, 2021, 51(3): 286-295. DOI: 10.1053/j.semnuclmed.2020.12.006.

6.王珊珊. 奥拉西坦辅助治疗缺血性脑卒中后认知功能障碍[J]. 医学新知杂志, 2018, 28(5): 559-561. [Wang SS. Oxiracetam adjunctive therapy for cognitive dysfunction after ischemic stroke[J]. Yixue Xinzhi Zazhi, 2018, 28(5): 559-561.] DOI: 10.3969/j.issn.1004-5511.2018.05.031.

7.段园园, 刘生刚, 肖雷, 等. 缺血性脑卒中急性期认知损伤的危险因素及其交互作用研究[J]. 华西医学, 2023, 38(5): 688-693. [Duan YY, Liu SG, Xiao L, et al. Risk factors and their interaction in cognitive impairment during the acute phase of ischemic stroke[J]. West China Medical Journal, 2023, 38(5): 688-693.] DOI: 10.7507/1002-0179.202303193.

8.Tyagi A, Pugazhenthi S. Targeting insulin resistance to treat cognitive dysfunction[J]. Mol Neurobiol, 2021, 58(6): 2672-2691. DOI: 10.1007/s12035-021-02283-3.

9.中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409. DOI: 10.3760/cma.j.cn115791-20210221-00095.

10.武锋超, 马兰虎, 蓝庆肃, 等. SGLT2抑制剂治疗心力衰竭的有效性和安全性的网状Meta分析[J]. 中国循证医学杂志, 2022, 22(3): 291-298. [Wu FC, Ma LH, Lan QS, et al. Network meta-analysis of the effectiveness and safety of SGLT2 inhibitors in the treatment of heart failure[J]. Chinese Journal of Evidence-Based Medicine, 2022, 22(3): 291-298.] DOI: 10.7507/1672-2531.202110075.

11.唐平, 孙致连, 程筱玲, 等. 达格列净或阿卡波糖联合二甲双胍对初诊2型糖尿病患者血糖波动的影响比较 [J]. 药物流行病学杂志, 2022, 31(7): 435-438. [Tang  P, Sun ZL, Cheng XL, et al. Comparison of the effects of dapagliflozin or acarbose combined with metformin on blood glucose fluctuations in newly diagnosed type 2 diabetes patients[J]. Chinese Journal of Pharmacoepidemiology, 2022, 31(7): 435-438.] DOI: 10.19960/j.cnki.issn1005-0698.2022.07.001.

12.Noel JA, Hougen I, Sood MM. The intersection of SGLT2 inhibitors, cognitive impairment, and CKD[J]. Front Neurol. 2022, 13: 823569. DOI: 10.3389/fneur.2022.823569.

13.Hierro-Bujalance C, Infante-Garcia C, Del Marco A, et al. Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes[J]. Alzheimers Res Ther, 2020, 12(1): 40. DOI: 10.1186/s13195-020-00607-4.

14.Tsai WH, Chuang SM, Liu SC, et al. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and Meta-analysis[J]. Sci Rep, 2021, 11(1): 15364. DOI: 10.1038/s41598-021-94945-4.

15.Zou CY, Liu XK, Sang YQ, et al. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a Meta-analysis[J]. Medicine, 2019, 98(49): e18245. DOI: 10.1097/MD.0000000000018245.

16.王小瑞, 郑献召, 韩凯, 等. 沙格列汀对2型糖尿病伴缺血性脑卒中患者血糖水平及认知功能的影响[J]. 新乡医学院学报, 2022, 39(12): 1163-1167. [Wang XR, Zheng XZ, Han K, et al. The effect of saxagliptin on blood glucose levels and cognitive function in patients with type 2 diabetes mellitus complicated with ischemic stroke[J]. Journal of Xinxiang Medical College, 2022, 39(12): 1163-1167.] DOI: 10.7683/xxyxyxb.2022.12.012.

17.何丰, 高洁. 二甲双胍对2型糖尿病伴缺血性脑卒中患者神经功能恢复的影响[J]. 按摩与康复医学, 2021, 12(12): 72-74. [He F, Gao J. The effect of metformin on the recovery of neurological function in patients with type 2 diabetes mellitus complicated with ischemic stroke[J]. Massage and Rehabilitation Medicine, 2021, 12(12): 72-74.] DOI: 10.19787/j.issn.1008-1879.2021.12.026.

18.中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国缺血性脑卒中和短暂性脑缺血发作二级预防指南2014[J]. 中华神经科杂志, 2015, 48(4): 258-273. DOI: 10.3760/cma.j.issn.1006-7876.2015.04.003.

19.Rizzo MR, Di Meo ID, Polito R, et al. Cognitive impairment and type 2 diabetes mellitus: focus of SGLT2 inhibitors treatment[J]. Pharmacol Res, 2022, 176: 106062. DOI: 10.1016/j.phrs.2022.106062.

20.佘莉莉. 达格列净对2型糖尿病患者血糖波动及氧化应激的影响研究[D]. 湖北荆州: 长江大学, 2019. https://cdmd.cnki.com.cn/Article/CDMD-10489-1019172519.htm.

21.Groeneveld ON, Moneti C, Heinen R, et al. The clinical phenotype of vascular cognitive impairment in patients with type 2 diabetes mellitus[J]. J Alzheimers Dis, 2019, 68(1): 311-322. DOI: 10.3233/JAD-180914.

22.Perna S, Mainardi M, Astrone P, et al. 12-month effects of incretins versus SGLT2-inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with type-2 diabetes mellitus[J]. Clin Pharmacol, 2018, 10: 141-151. DOI: 10.2147/CPAA.S164785.

23.Cheng H, Zhang Z, Zhang B, et al. Enhancement of impaired olfactory neural activation and cognitive capacity by liraglutide, but not dapagliflozin or acarbose, in patients with type 2 diabetes: a 16-week randomized parallel comparative study[J]. Diabetes Care, 2022, 45(5): 1201-1210. DOI: 10.2337/dc21-2064.

24.Sa-Nguanmoo P, Tanajak P, Kerdphoo S, et al. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats[J]. Toxicol Appl Pharmacol, 2017, 333: 43-50. DOI: 10.1016/j.taap.2017.08.005.

25.Shaikh S, Rizvi SM, Shakil S, et al. Forxiga (dapagliflozin): plausible role in the treatment of diabetes-associated neurological disorders[J]. Biotechnol Appl Biochem, 2016, 63(1): 145-150. DOI: 10.1002/bab.1319.